Gayton JL. Etiology, prevalence, and treatment of dry eye disease. Clin Ophthalmol. 2009;3:405–412. doi:10.2147/OPTH.S5555
PubMedGoogle Scholar
Semba CP, Gadek TR. Development of lifitegrast: a novel T-cell inhibitor for the treatment of dry eye disease. Clin Ophthalmol. 2016;10:1083–1094. doi:10.2147/OPTH.S110557
PubMed Web of Science ®Google Scholar
Phadatare SP, Momin M, Nighojkar P, Askarkar S, Singh KK. A comprehensive review on dry eye disease: diagnosis, medical management, recent developments, and future challenges. Adv Pharm. 2015;2015:1–12. doi:10.1155/2015/704946
Google Scholar
Farrand KF, Fridman M, Stillman IO, Schaumberg DA. Prevalence of diagnosed dry eye disease in the United States among adults aged 18 years and older. Am J Ophthalmol. 2017;182:90–98. doi:10.1016/j.ajo.2017.06.033
PubMed Web of Science ®Google Scholar
Caffery B, Srinivasan S, Reaume CJ, et al. Prevalence of dry eye disease in Ontario, Canada: a population-based survey. Ocul Surf. 2019;17(3):526–531. doi:10.1016/j.jtos.2019.02.011
PubMed Web of Science ®Google Scholar
Elhusseiny AM, Khalil AA, El Sheikh RH, Bakr MA, Eissa MG, El Sayed YM. New approaches for diagnosis of dry eye disease. Int J Ophthalmol. 2019;12(10):1618–1628. doi:10.18240/ijo.2019.10.15
PubMed Web of Science ®Google Scholar
Barta Z, Czompa L, Rentka A, et al. Evaluation of objective signs and subjective symptoms of dry eye disease in patients with inflammatory bowel disease. Biomed Res Int. 2019;2019:8310583. doi:10.1155/2019/8310583
Web of Science ®Google Scholar
Alunno A, Bartoloni E, Valentini V, et al. Discrepancy between subjective symptoms, objective measures and disease activity indexes: the lesson of primary sjogren’s syndrome. Clin Exp Rheumatol. 2018;36 Suppl 112(3):210–214.
Web of Science ®Google Scholar
Giannaccare G, Vaccaro S, Mancini A, Scorcia V. Dry eye in the COVID-19 era: how the measures for controlling pandemic might harm ocular surface. Graefes Arch Clin Exp Ophthalmol. 2020;258(11):2567–2568. doi:10.1007/s00417-020-04808-3
PubMed Web of Science ®Google Scholar
Uchino M, Schaumberg DA. Dry eye disease: impact on quality of life and vision. Curr Ophthalmol Rep. 2013;1(2):51–57. doi:10.1007/s40135-013-0009-1
PubMedGoogle Scholar
Dry eyes. Mayo clinic. September 24, 2020. Available from: https://www.mayoclinic.org/diseases-conditions/dry-eyes/diagnosis-treatment/drc-20371869. Accessed November 18, 2020.
Google Scholar
FDA. Drug approval package: CEQUA. Drug Approvals and Databases. 2019. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/210913Orig1s000TOC.cfm. Accessed November 15, 2020.
Google Scholar
SHIRE. Optometrists vs. ophthalmologists. Dry Eye Diagnosis. 2019. Available from: https://www.xiidra.com/dry-eye-diagnosis/optometrist-vs-ophthalmologist. Accessed November 15, 2020.
Google Scholar
FDA. FDA approves new medication for dry eye disease. Press Announcements. 2016. Available from: https://www.fda.gov/news-events/press-announcements/fda-approves-new-medication-dry-eye-disease. Accessed November 15, 2020.
Google Scholar
Holland EJ, Luchs J, Karpecki PM, et al. Lifitegrast for the treatment of dry eye disease: results of a Phase III, randomized, double-masked, placebo-controlled trial (OPUS-3). Ophthalmology. 2017;124(1):53–60. doi:10.1016/j.ophtha.2016.09.025
PubMed Web of Science ®Google Scholar
Sheppard JD, Torkildsen GL, Lonsdale JD, et al. Lifitegrast ophthalmic solution 5.0% for treatment of dry eye disease: results of the OPUS-1 Phase 3 study. Ophthalmology. 2014;121(2):475–483. doi:10.1016/j.ophtha.2013.09.015
PubMed Web of Science ®Google Scholar
Tauber J, Karpecki P, Latkany R, et al. Lifitegrast ophthalmic solution 5.0% versus placebo for treatment of dry eye disease: results of the randomized phase III OPUS-2 study. Ophthalmology. 2015;122(12):2423–2431. doi:10.1016/j.ophtha.2015.08.001
PubMed Web of Science ®Google Scholar
Okumura Y, Inomata T, Iwata N, et al. A review of dry eye questionnaires: measuring patient-reported outcomes and health-related quality of life. Diagnostics. 2020;10(8):559.
Web of Science ®Google Scholar
Bron AJEV, Smith JA. Grading of corneal and conjunctival staining in the context of other dry eye tests. Cornea. 2003;7:640–650. doi:10.1097/00003226-200310000-00008
Web of Science ®Google Scholar
Tong AY, Passi SF, Gupta PK. Clinical outcomes of lifitegrast 5% ophthalmic solution in the treatment of dry eye disease. Eye Contact Lens. 2020;46(Suppl 1):S20–S24. doi:10.1097/ICL.0000000000000601
Web of Science ®Google Scholar
White DE, Zhao Y, Ogundele A, et al. Real-world treatment patterns of cyclosporine ophthalmic emulsion and lifitegrast ophthalmic solution among patients with dry eye. Clin Ophthalmol. 2019;13:2285–2292. doi:10.2147/OPTH.S226168
PubMed Web of Science ®Google Scholar

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.

People also read
Recommended articles
Cited by

To cite this article:

Reference style: APA Chicago Harvard

Citation copied to clipboard

Reference styles above use APA (6th edition), Chicago (16th edition) & Harvard (10th edition)

Download citation

Download a citation file in RIS format that can be imported by citation management software including EndNote, ProCite, RefWorks and Reference Manager.

Choose format: RIS BibTex RefWorks Direct Export

Choose options: Citation Citation & abstract Citation & references

Real-World Experience with Lifitegrast Ophthalmic Solution (Xiidra^®) in the US and Canada: Retrospective Study of Patient Characteristics, Treatment Patterns, and Clinical Effectiveness in 600 Patients with Dry Eye Disease

References

Information for

Open access

Opportunities

Help and information

Your download is now in progress and you may close this window

Login or register to access this feature

Real-World Experience with Lifitegrast Ophthalmic Solution (Xiidra®) in the US and Canada: Retrospective Study of Patient Characteristics, Treatment Patterns, and Clinical Effectiveness in 600 Patients with Dry Eye Disease